| Name | Title | Contact Details |
|---|
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent`s lead therapeutic candidate, PLX9486 (expected to be named CGT9486 in the future), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying PLX9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.
Co-Founded by world-renowned mycologist Paul Stamets, MycoMedica, PBC is a life sciences company developing therapeutic drugs derived from fungi to help people live healthier, better lives.
Calysta, Inc., Menlo Park, CA, is a biotechnology company working towards a future where the world`s growing population has guaranteed food security. Calysta`s aim is to make more from less by fermenting natural gas to create new food products, creating sustainable, high value nutritional ingredients that don`t interfere with the human food chain.
Synthes is a leading global medical device company. Through its five product groups (Trauma, Spine, Cranio-Maxillofacial, Biomaterials and Power Tools) it develops, produces and markets instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.
We are a global biotechnology company, specializing in discovering, developing, and delivering innovative therapies for the treatment of neurodegenerative, non-malignant hematologic and autoimmune diseases to patients worldwide. As a company, we are focused on cutting-edge science and medicines that address unmet patient needs and change the course of these devastating diseases. Founded in 1978, we are the world`s oldest independent biotechnology company and take pride in being known for pioneering the development of leading multiple sclerosis therapies. With approximately 7,000 employees worldwide, we are focused on better understanding the underlying biology of diseases so we can discover and deliver innovative treatments that make a real difference in the lives of patients. We also put great focus on being good corporate citizens. Our commitment to corporate citizenship extends to patient education and support programs, giving back to the communities in which we operate, promoting and advancing science education, and operating in a sustainable manner. These cultural imperatives are directly incorporated into our business activities.